各種心不全モデルにおける分子状水素の可能性：レビュー
Heart failure (HF) is a complex clinical syndrome with rising global prevalence, characterized by impaired cardiac pumping capacity and a 5-year mortality rate reaching up to 75%. Following initial cardiac events such as myocardial infarction or hypertension, compensatory mechanisms are activated; however, their sustained engagement drives pathological cardiac remodeling and hypertrophy. This review—described as the first to consolidate findings across diverse HF models—examines evidence that molecular hydrogen (H2) confers cardioprotective benefits through multiple mechanisms, including attenuation of oxidative stress, suppression of inflammatory signaling, reduction of cardiomyocyte death, preservation of mitochondrial function and cellular metabolism, and modulation of cardiac remodeling processes such as hypertrophy and fibrosis. The authors conclude that while existing data are encouraging, the feasibility and efficacy of H2 application in distinct HF subtypes require further systematic investigation.
H2 exerts cardioprotection by reducing oxidative stress and inflammatory signaling, limiting cardiomyocyte apoptosis, preserving mitochondrial function and metabolic homeostasis, and attenuating pathological cardiac remodeling including hypertrophy and fibrosis.
This study combines multiple delivery routes. As a general principle, the most efficient route for routine hydrogen intake is inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/41373725